Novel Transdermal Formulation for Treatment of Type 2 Diabetes - - PowerPoint PPT Presentation

Novel Transdermal Formulation for Treatment of Type 2 Diabetes

Reducta Biosciences

• We have invented the synthetic steroid Fluasterone, a

modified DHEA derivative

• Fluasterone mimics the properties of DHEA

(Dehydroepiandrosterone)

• DHEA produces marked anti-diabetic, anti-

inflammatory, anti-obesity and anti-cancer effects in mice and rats

• Fluasterone works through unique anti-

glucocorticoid and anti-inflammatory mechanisms

Major Potential Advantages of Fluasterone

• Fluasterone works through unique anti-glucocorticoid and

anti-inflammatory mechanisms

• Applied topically – no needles
• Lowered fasting plasma glucose levels in pre-diabetics
• Lowered triglyceride levels in hyperglyceridimic patients
• Both preclinical studies and human epidemiological findings suggest

Fluasterone may reduce the incidence of cardiovascular disease in type 2 diabetics

• Since cardiovascular disease is the number 1 cause of morbidity and

mortality in type 2 diabetics, and none of the current anti-diabetic drugs have been shown to reduce this disease, Fluasterone has great potential promise over existing drugs